The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Bleeding Risk with Dabigatran in the Frail Elderly
Open accessAbstract
In response to Eikelboom and Weitz: when prescribing a drug with side effects that include life-threatening hemorrhage, reversal is not "desirable," it is essential.Our letter to the Editor never mentioned prothrombin complex concentrates.Rapid reversal is indeed associated with reduced morbidity and mortality.[1][2][3] Thromboelastography detects the effects of dabigatran within minutes (and the values for activated clotting time were markedly prolonged in all the patients described in our letter).Partialthromboplastin times were normal.The dilutethrombin-time assay with dabigatran calibrators is currently labeled for research use only.Eikelboom and Weitz state the deaths could not be attributed to "lack of an antidote."These patients were receiving dabigatran and presented with coagulopathy, and the multidisciplinary team caring for them could not control their hemorrhages.Next, although an absolute reduction of 0.2 percentage points in intracranial hemorrhage may be statistically significant (in 18,000 patients), this may not be clinically meaningful.4 Finally, they state that a lack of an antidote should not deter physicians from prescribing dabigatran.We hope all prescribers will take note of the Food and Drug Administration alert re-garding dabigatran and, in doing so, expand the risk-benefit conversation with their patients.5
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Poli, D., Antonucci, E., Testa, S., Tosetto, A., Ageno, W., Palareti, G., & for the Italian Federation of Anticoagulation Clinics (FCSA) (2011) · Circulation · doi:10.1161/circulationaha.110.007864 · Cited by 194
Cited by
National trends in ambulatory oral anticoagulant use
Barnes, G. D., Lucas, E., Alexander, G. C., & Goldberger, Z. D. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.05.044 · Cited by 598
Narouze, S., Benzon, H. T., Provenzano, D. A., Buvanendran, A., De Andres, J., Deer, T. R., Rauck, R., & Huntoon, M. A. (2015) · Regional Anesthesia and Pain Medicine · doi:10.1097/aap.0000000000000223 · Cited by 362
Guidance for the practical management of the direct oral anticoagulants (DOACs) in VTE treatment
Burnett, A. E., Mahan, C. E., Vazquez, S. R., Oertel, L. B., Garcia, D. A., & Ansell, J. (2016) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-015-1310-7 · Cited by 333
Bleeding and Coagulopathies in Critical Care
Hunt, B. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1208626 · Cited by 324
Management and Outcomes of Major Bleeding During Treatment With Dabigatran or Warfarin
Majeed, A., Hwang, H.-G., Connolly, S. J., Eikelboom, J. W., Ezekowitz, M. D., Wallentin, L., Brueckmann, M., Fraessdorf, M., Yusuf, S., & Schulman, S. (2013) · Circulation · doi:10.1161/circulationaha.113.002332 · Cited by 277
Metadata
- Authors
- Harper, P., Young, L., & Merriman, E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-03
- Volume
- 366
- Issue
- 9
- Pages
- 864-866
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1975650244
- Cited by
- 285
- References
- 2
- FWCI
- 37.02
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Bleeding Risk with Dabigatran in the Frail Elderly. https://app.cochat.ai/papers/10.1056/nejmc1112874
- The paper
- Harper, P., Young, L., & Merriman, E. (2012). Bleeding Risk with Dabigatran in the Frail Elderly. New England Journal of Medicine. https://doi.org/10.1056/nejmc1112874
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.